SCHEMBL29520993

SCHEMBL29520993

CN(c1ccccn1)n1ncc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.45
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
KDM4E B2RXH2 3/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
CASP1 P29466 1/20 0.37
RAB9A P51151 1/20 0.37
CASP7 P55210 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
DYRK1A Q13627 5/20 0.36
ADRA2A P08913 3/20 0.35
ADRA2B P18089 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29520621 0.76 SLC6A2 (0.63) SLC6A2KDM4ELMNASMN1; SMN2MEN1
SCHEMBL29520705 0.71 SLC6A2 (0.47) SLC6A2KDM4ELMNASMN1; SMN2MEN1
SCHEMBL6006426 0.70 SLC6A2 (0.46) SLC6A2KDM4ELMNASMN1; SMN2MEN1
SCHEMBL6008594 0.70 SLC6A2 (0.46) SLC6A2KDM4ELMNASMN1; SMN2MEN1
SCHEMBL231127 0.65 CYP2D6 (0.57) SLC6A2CYP2D6CYP2C19KDM4ELMNA
SCHEMBL29635663 0.65
SCHEMBL364 0.65
SCHEMBL31020506 0.65 IRAK4 (0.57) KDM4EALDH1A1GAARAB9AMKNK2
SCHEMBL12075537 0.65 IRAK4 (0.57) KDM4EALDH1A1GAARAB9AMKNK2
SCHEMBL16796145 0.64 MKNK1 (0.51) KDM4ERECQLMKNK2IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649255-B2 Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same 1ST Biotherapeutics, Inc. (KR) 2023-05-16 US disclosed
US-20220098193-A1 INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME 1ST Biotherapeutics, Inc. 2022-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649255-B2 Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same IP6K1, HIPK1, IP6K3 SLC6A2 4822/4885CYP2D6 2610/4885CYP2C19 1320/4885
US-20220098193-A1 INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME IP6K1, HIPK1, IP6K3 SLC6A2 4822/4885CYP2D6 2610/4885CYP2C19 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.